Primary tabs

Other Access

The information on this page (the dataset metadata) is also available in these formats.

JSON RDF

via the DKAN API

A PHASE III RANDOMIZED OPEN-LABEL 3-ARM STUDY TO DETERMINE THE EFFICACY AND SAFETY OF LENALIDOMIDE REVLIMID PLUS LOW-DOSE DEXAMETHASONE WHEN GIVEN UNTIL PROGRESSIVE DISEASE OR FOR 18 FOUR-WEEK CYCLES VERSUS THE COMBINATION OF MELPHALAN PREDNISONE...

To compare the efficacy of lenalidomide plus low-dose dexamethasone given until progressive disease to that of the combination of melphalan prednisone and thalidomide given for 12 six-week cycles

FieldValue
Modified
2019-06-30
Release Date
2018-05-12
Identifier
34c0d378-b609-4e7b-8547-bd0e137528ac
License
Public Access Level
Public